Back to top
more

ResMed (RMD)

(Real Time Quote from BATS)

$243.86 USD

243.86
505,837

-0.42 (-0.17%)

Updated Nov 4, 2024 03:14 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value A Growth A Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 30% (74 out of 250)

Industry: Medical - Products

Better trading starts here.

Zacks News

Exact Sciences (EXAS) Q4 Earnings and Revenues Rise Y/Y

Exact Sciences' (EXAS) fourth-quarter 2019 results reflect strong segmental performances.

LabCorp (LH) Rides on Solid Diagnostics Despite PAMA Issues

LabCorp's (LH) Covance Drug Development delivers organic growth despite foreign currency headwind.

Here's Why You Should Add Hill-Rom to Your Portfolio Now

Investor confidence is at a high, thanks to Hill-Rom (HRC) solid prospects.

STERIS (STE) Surpasses Q3 Earnings Estimates, Ups FY20 View

STERIS' (STE) third-quarter fiscal 2020 results reflect strong segmental performances.

Swayta Shah headshot

Buy These 5 Stocks With Attractive Sales Growth Right Now

Sales growth is an important metric for any company, as it is a vital part of growth projections and instrumental in strategic decision making.

Here's Why You Should Add Zimmer (ZBH) to Your Portfolio

Investors continue to be optimistic about Zimmer's (ZBH) potential on its strong segmental and international results for the fiscal fourth quarter.

Hologic Expands Panther Portfolio With New Product Offerings

Hologic's (HOLX) latest offerings are set to improve flexibility and efficiency of laboratories.

Omnicell (OMCL) Lags Q4 Earnings Estimates, Beats on Revenues

Omnicell (OMCL) fourth-quarter 2019 results reflect strong segmental performances.

ResMed (RMD) Rides on New Product Portfolio, SaaS Growth

Within SaaS, ResMed (RMD) consistently gains momentum from the Brightree service portfolio and derives synergies from the accretive MatrixCare buyout.

Here's Why You Should Add ResMed (RMD) to Your Portfolio

Investors continue to be optimistic about ResMed (RMD), given its strong segmental and international fiscal second-quarter results.

Zacks.com featured highlights include: MSFT, RUTH, RMD, CDNS, CRL and MXIM

Zacks.com featured highlights include: MSFT, RUTH, RMD, CDNS, CRL and MXIM

ResMed (RMD) Stock Hits New 52-Week High: What's Driving It?

ResMed (RMD) is optimistic about maintaining growth momentum on several recent developments.

Haemonetics (HAE) Q3 Earnings & Revenues Beat, Margins Expand

Haemonetics (HAE) fiscal third-quarter 2020 results reflect strong performances in Plasma and Hospital segments.

Boston Scientific (BSX) Q4 Earnings Beat, Margins Decline

Boston Scientific (BSX) is steadily investing in new technologies as well as the global markets, reflecting its uptick in sales across most geographies in Q4.

Here's Why You Should Retain IDEXX Laboratories Stock Now

Investor confidence remains high in IDEXX (IDXX) stock, thanks to solid prospects.

6 GARP Stocks to Scoop Up for Maximum Returns

If you're looking for a profitable portfolio of stocks that will offer the best of value and growth investing, try the growth at a reasonable price or GARP strategy.

ResMed (RMD) Q2 Earnings Beat Estimates, Margins Expand

ResMed (RMD) exhibits robust growth in the second quarter of fiscal 2020, fueled by the strong performance of both its segment.

ResMed (RMD) Q2 Earnings and Revenues Top Estimates

ResMed (RMD) delivered earnings and revenue surprises of 19.80% and 1.49%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?

Sriparna Ghosal headshot

COPD Devices Gain Regulatory Go-Ahead: 3 Stocks in Focus

Growth in the COPD devices market can be attributed to factors like steadily rising geriatric population, increasing incidence of smoking and chronic respiratory diseases.

ResMed (RMD) Earnings Expected to Grow: What to Know Ahead of Next Week's Release

ResMed (RMD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

ResMed Launches AirFit F30i CPAP Mask, Widens Client Base

ResMed (RMD) launches its first tube-up, full-face CPAP mask, thus completing its full-face mask portfolio.

NUVA vs. RMD: Which Stock Is the Better Value Option?

NUVA vs. RMD: Which Stock Is the Better Value Option?

Strong Pipeline Aids Tandem Diabetes Despite Stiff Rivalry

Tandem Diabetes' (TNDM) products under development comprise AID systems, a next-generation hardware platform and connected (mobile) health offerings.

Product Launches Aid Intersect ENT (XENT) Despite Cost Woes

Intersect ENT (XENT) recently closes its ENCORE study, a small 50-patient open label program designed to evaluate the safety of the repetitive use of SINUVA.

Bruker (BRKR) Rides High on Strong Nano Sales, New Buyouts

Bruker (BRKR) is reaping solid synergy benefits from the acquisitions of Anasys, JPK and Alicona.